Neuroone Medical Technologies Corporation · NASDAQ:NMTC
Neuroone Medical Technologies — Investor Presentation (January 2025)
19 slides from Neuroone Medical Technologies's investor presentation, Jan 10, 2025
Slide 1: Investor Presentation January 2025
Investor Presentation January 2025 NASDAQ: NMTC
Slide 2: Forward-Looking Statements
2 Caution: Federal law restricts this device to sale by or on the order of a physician. Forward - Looking Statements This presentation contains forward - looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of
Slide 3: NeuroOne is a medical technology company transforming diagnosis and treatment of neurological disorders
NeuroOne is a medical technology company that is transforming the diagnosis and treatment of neurological disorders 3 FDA 510(k) cleared products for use in the brain, with the only FDA cleared product that uses the same sEEG electrode for both diagnostic and therapeutic applications. Additional sub
Slide 4: Thin Film & Flexibility
Thin Film & Flexibility 4 NeuroOne’s next - generation electrode platform is highly disruptive and differentiated Multi - Purpose Device Since the 1950s, clinicians and researchers have used first generation electrodes for the recording and stimulation of brain tissue. NeuroOne’s multi - purpose ele
Slide 5: Mayo Clinic partnership
Mayo Clinic partnership • Mayo Clinic began testing technology in pre - clinical models and clinical research in 2015 • Mayo Clinic leading neurologist, Dr. Worrell, chairs the NeuroOne Scientific Advisory Board • First commercial human use of Evo® Cortical Electrodes performed at Mayo Clinic in Nov
Slide 6: Zimmer Biomet partnership
Zimmer Biomet partnership • Zimmer is a worldwide leader in robotic technology used in minimally invasive neurosurgeries • Evo® electrodes are complementary to Zimmer’s ROSA ONE ® robotic neurosurgery platform • Partnership initiated in 2020: $5.5 million total paid to NeuroOne under initial contrac
Slide 7: Our electrode platform addresses a multi-billion $ and growing market
7 Our electrode platform addresses a multi - billion $ and growing market needs¹ $100M Brain Ablation $500M+ Parkinson’s $3B Spinal Cord Stimulation (Back Pain) $100M Epilepsy (Diagnostic Only) $1B+ $1B+ $5B+ $10B+ $0 Drug Delivery $10B+ Actual Market Potential Market Size 1. Company data on file NA
Slide 8: Technology platform
Technology platform 8 NASDAQ: NMTC
Slide 9: Product Portfolio
Product Portfolio Application Status Use Case Product Diagnostic Currently marketed by Zimmer Biomet Recording brain activity Placed on surface of brain Evo® Cortical Electrodes Diagnostic Currently marketed by Zimmer Biomet Recording brain activity Placed Deeper Into the Brain Evo® sEEG Electrodes
Slide 10: Thin-Film Evo sEEG & Cortical Electrodes
Thin - Film Evo® sEEG & Cortical Electrodes NASDAQ: NMTC 10
Slide 11: OneRF Ablation System
OneRF TM Ablation System Recently expanded Zimmer Biomet Partnership to distribute system NASDAQ: NMTC 11
Slide 12: Spinal Cord Percutaneous Paddle Lead
Spinal Cord Percutaneous Paddle Lead NASDAQ: NMTC 12
Slide 13: sEEG-Based Drug Delivery System
sEEG - Based Drug Delivery System Designed to leverage our sEEG platform enabling drug delivery + brain activity recording NASDAQ: NMTC 13
Slide 14: Our management team
Our management team Dave Rosa President & Chief Executive Officer Ron McClurg Chief Financial Officer Ron McClurg Chief Technology Officer Mark Christianson Co - Founder, Business Development Director, Medical Sales Liaison Hijaz Haris Vice - President of Marketing Camilo Diaz Botia Director of Elec
Slide 15: Financial overview
• Decreasing burn rate in FY2024 • Expected FY2025 product revenue of $8 - $10M, an increase of 132% - 190% vs FY2024 • Expected FY2025 gross margin of 47% - 51% • More potential partnerships focused on pain management and drug delivery • Debt free balance sheet 15 Financial overview Highlights & Fi
Slide 16: Financial overview: FY2025 guidance
• Debt free balance sheet • Decreasing burn rate in FY2024 • FY2025 Guidance: • FY 2025 product revenue of $8.0 - $10.0M (132% - 190% increase vs. FY2024) • FY2025 product gross margin of 47% - 51% • New potential partnerships focused on pain management and drug delivery Financial overview Highlight
Slide 17: Upcoming potential catalysts
Upcoming potential catalysts 17 • Zimmer Biomet OneRF® Ablation System full launch • Potential revenue in calendar 2025 for facial pain ablation system • Electrode revenue expected to more than double in FY2025 • Non - dilutive licensing agreement for ablation system with Zimmer Biomet with future p
Slide 18: Key takeaways
Key takeaways NASDAQ: NMTC 18
Slide 19: Thank you
Thank you NASDAQ: NMTC Dave Rosa Chief Executive Officer ir@nmtc1.com
NeuroOne Medical Technologies — Investor Presentation (January 2025) on 6ix